Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia
Table 2
Plasma lipid levels (mmol/L) in patients with chronic renal insufficiency (n = 23) and healthy reference subjects (n = 17) at start and end of treatment with 1 mg tesaglitazar o.d. Mean and standard deviation (in parenthesis).
CKD patients
Healthy reference group
At entry
After 6 weeks
Estimated change
After 3 weeks of drug
At entry
After 6 weeks
Estimated change
After 3 weeks of drug
Total cholesterol
6.4 (1.3)
5.7 (1.3)
−12%***
6.3 (1.2)
5.3 (0.7)
4.6 (0.5)
−14%***
5.0 (0.6)
Triglycerides
2.0 (1.9)
1.2 (0.9)
−40%***
1.7 (1.1)
1.1 (0.4)
0.7 (0.3)
−34%***
1.1 (0.4)
VLDL-cholesterol
0.8 (0.4)
0.5 (0.3)
−40%***
0.8 (0.5)
0.5 (0.2)
0.3 (0.1)
−34%***
0.5 (0.2)
LDL-cholesterol
4.2 (0.81)
3.5 (1.2)
−21%***
4.2 (1.0)
3.4 (0.7)
2.7 (0.6)
−20%**
3.1 (0.6)
HDL-cholesterol
1.2 (0.2)
1.6 (0.4)
+24%***
1.4 (0.3)
1.5 (0.4)
1.5 (0.4)
+2%
1.4 (0.3)
P < 0.01 and ***P < 0.001 with group comparison between baseline and after 6 weeks of treatment.
